Perrigo Company Earnings Call Transcripts
Fiscal Year 2026
-
A leading OTC health provider reported strong market share gains, significant cost savings, and a focused strategy on innovation, portfolio simplification, and disciplined capital allocation. Despite market softness, stabilization is expected in H2 2026, with long-term growth driven by brand building and geographic expansion.
Fiscal Year 2025
-
Delivered strong share gains and EPS growth in 2025 despite market softness, with 2026 set as a transition year facing temporary headwinds but expecting improvement in the second half. Operational enhancements and portfolio streamlining continue, with a focus on innovation and cost savings.
-
Sustained share gains in U.S. and European OTC categories offset soft market conditions, but weaker-than-expected OTC and Infant Formula performance led to a downward revision of 2025 guidance. Strategic reviews of Infant Formula and Oral Care are underway, with a focus on deleveraging and high-performing brands.
-
Disciplined execution of the 3S strategy is driving share gains in store brands, strong recovery in infant formula, and robust financial performance. Innovation, portfolio expansion, and operational improvements support confidence in 2025-2027 growth targets.
-
Second quarter results showed flat organic net sales, margin pressure from divestitures and infant formula issues, but strong EPS and operating income growth YTD. The outlook for EPS and margins is reaffirmed, with growth expected to accelerate in the second half, driven by new OTC contracts and infant formula recovery.
-
A leading self-care provider outlined its 3S strategy to stabilize, streamline, and strengthen operations, targeting $100–$200M incremental revenue from high-growth brands by 2027 and double-digit EPS growth in 2025. The company is leveraging its diversified portfolio, scaling innovation, and managing tariff risks while aiming to reduce net leverage below 3x.
-
Q1 2025 saw strong profit and margin growth, led by infant formula recovery and robust OTC brand performance, despite a slight organic sales decline. Guidance for EPS and leverage was reaffirmed, with a wider sales outlook due to macro uncertainty and tariffs.
-
Management outlined a three-year plan targeting 2.5%-4.5% organic growth, margin expansion, and significant free cash flow improvement, driven by branded portfolio acceleration, infant formula recovery, and operational streamlining. Portfolio optimization and disciplined capital allocation support long-term shareholder value.
-
Management presented a focused 3S Plan to drive growth, margin expansion, and predictable results through 2027, prioritizing high-growth brands and operational efficiency. Financial guidance targets 2.5%-4.5% organic sales CAGR, significant margin expansion, and strong free cash flow, supported by major investments in supply chain and innovation.
Fiscal Year 2024
-
Q3 saw strong margin and operating income growth, driven by cost savings and infant formula recovery, despite a year-over-year sales decline. Guidance for 2024 EPS is reaffirmed, with continued focus on cost efficiency, innovation, and stabilizing core businesses.
-
Management outlined a strategy focused on branded growth, cost savings, and infant formula recovery, with strong progress in refinancing and deleveraging. Opill is gaining traction, and 2025 EPS targets hinge on continued margin expansion and operational improvements.
-
Strong growth in private label and branded products is driving margin expansion, with cost-saving initiatives and innovation supporting future performance. Infant formula recovery, Opill, and European branded growth are key drivers, while capital allocation flexibility is expected as leverage targets are met.
-
Second quarter saw a 9.1% organic net sales decline, mainly from infant formula and seasonal headwinds, but gross and operating margins expanded. Full-year EPS guidance is reaffirmed, with margin improvements and new contract wins expected to offset sales headwinds in 2025.
-
The company is executing on cost-saving and operational initiatives, with infant formula normalization and branded product growth driving near-term performance. Guidance remains unchanged despite seasonal headwinds, and EPS is expected to exceed $3 in 2025 as leverage improves and strategic focus sharpens.